SINGAPORE, August 28, 2025 — Leads & Copy — EUDA Health Holdings Limited (NASDAQ: EUDA) has signed a Letter of Intent to potentially acquire Chemokine Pte Ltd. EUDA will conduct due diligence on Chemokine, which has agreed to an exclusivity period of 120 days. Chemokine is a Singapore-based biotech company focused on molecular supplements and gene modulating formulations, including an immune health supplement for which EUDA has exclusive worldwide distribution rights, marketed under the brand name Euda Helixé.
Chemokine was founded by Professor Kah Meng Lim, a molecular medicine researcher. Euda Helixé supports energy, immune resilience, and cellular health using a formulation that combines molecular deer placenta, marine collagen, and bioactive antioxidants. It is designed to modulate gene expression by activating beneficial genes while silencing harmful ones.
EUDA Health Holdings Limited aims to be a market leader in non-invasive and preventive healthcare, focusing on the longevity sector in Singapore, Malaysia, and China.
Contact: Linda Bergkamp, Christensen Advisory, Phone: +1-480-614-3004, E-mail: linda.bergkamp@christensencomms.com
Source: EUDA Health Holdings Limited
